AzaSite (azithromycin ophthalmic solution) + Vigamox (moxifloxacin hydrochloride ophthalmic solution)
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Bacterial Infections
Conditions
Bacterial Infections, Eye Infections
Trial Timeline
Mar 1, 2008 → —
NCT ID
NCT00575367About AzaSite (azithromycin ophthalmic solution) + Vigamox (moxifloxacin hydrochloride ophthalmic solution)
AzaSite (azithromycin ophthalmic solution) + Vigamox (moxifloxacin hydrochloride ophthalmic solution) is a approved stage product being developed by Merck for Bacterial Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00575367. Target conditions include Bacterial Infections, Eye Infections.
What happened to similar drugs?
4 of 20 similar drugs in Bacterial Infections were approved
Approved (4) Terminated (2) Active (15)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00575367 | Approved | Completed |
Competing Products
20 competing products in Bacterial Infections